Tackling antimalarial drug resistance today and preparing for the future

30 Jul 2019

During the past 20 years, artemisinin-based medicines have contributed to a decrease in malaria-related mortality. Looking ahead to the next 20, resistance to these medicines will be one of the toughest challenges we will face. Today, we are seeing the first signs of such resistance in Africa. Take a look at this image slideshow to learn about how MMV is approaching this issue today and preparing for the future. 

  • Photos:

    Slide 1- Toby Madden/ Transaid; Slide 2- Damien Schumann; Slide 3- National Institute of Allergy and Infectious Diseases (NIAID), licensed under the Attribution 2.0 Generic license; Slide 4- Novartis; Slide 5- Damien Schumann; Slide 6-Shutterstock/Darren Baker; Slide 7- Anna Wang/MMV; Slide 8- Damien Schumann/MMV; Slide 9- Elizabeth Poll/MMV; Slide 10- Toby Madden/MMV